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The  manipulation  of  the  RNA  interference  pathway  using  small  interfering  RNA  (siRNA)
has  become  the  most  frequently  used  gene  silencing  method.  However,  siRNA  delivery
into  primary  cells,  especially  primary  macrophages,  is  often  considered  challenging.  Here
we  report  the investigation  of  the  suitability  of two  methodologies:  transient  transfection
and  electroporation,  to  deliver  siRNA  targeted  against  the putative  immunomodulatory
gene  Mediterranean  fever  (MEFV)  into  primary  bovine  monocyte-derived  macrophages
(bMDM).  Eleven  commercial  transfection  reagents  were  investigated  with  variable  results
with  respect  to siRNA  uptake,  target  gene  knock-down,  cell  toxicity  and  type I interferon
(IFN)  response  induction.  Three  transfection  reagents:  Lipofectamine  2000,  Lipofectamine
RNAiMAX  and  DharmaFECT  3, were  found  to consistently  give  the  best  results.  However,
all  the transfection  reagents  tested  induced  an  IFN  response  in  the  absence  of siRNA,
which  could  be  minimized  by reducing  the transfection  reagent  incubation  period.  In  addi-
tion,  optimized  siRNA  delivery  into  bMDM  by electroporation  achieved  comparable  levels
of target  gene  knock-down  as  transient  transfection,  without  a  detectable  IFN  response,
but  with  higher  levels  of cell  toxicity.  The  optimized  transient  transfection  and electro-
poration  methodologies  may  provide  a starting  point  for optimizing  siRNA  delivery  into
macrophages  derived  from  other  species  or other  cells  considered  difﬁcult  to  investigate
with  siRNA.
©  2014  The  Authors.  Published  by  Elsevier  B.V.  This  is an  open  access  article  under  the  CC
BY  license  (http://creativecommons.org/licenses/by/3.0/).1. Introduction
The discovery of the RNA inference (RNAi)
pathway, where double-stranded RNA (dsRNA) post-
transcriptionally silences gene expression (Fire et al.,
1998) and the subsequent demonstration that this
pathway could be utilized with short, exogenous RNA
sequences (Elbashir et al., 2001) have revolutionized
∗ Corresponding author. Tel.: +44 131 6519100; fax: +44 131 6519105.
E-mail address: Kirsty.Jensen@roslin.ed.ac.uk (K. Jensen).
http://dx.doi.org/10.1016/j.vetimm.2014.02.002
0165-2427/© 2014 The Authors. Published by Elsevier B.V. This is an open 
licenses/by/3.0/).many areas of cellular research. The RNAi pathway is
evolutionary conserved, being present in plants, fungi and
animal cells, and has multiple functions; protecting cells
from viral dsRNA and transposons, as well as regulating
gene expression by the degradation of mRNA, translational
repression and chromatin modiﬁcations (reviewed by
Dykxhoorn and Lieberman, 2005). In the cell cytoplasm,
endogenous microRNA (miRNA) or exogenous dsRNA are
typically processed into 21–23 nucleotide short interfering
RNA (siRNA) by the Dicer protein and integrated into the
multi-subunit RNA-induced silencing complex (RISC). The
RNA strands are separated and the antisense (guide) strand
access article under the CC BY license (http://creativecommons.org/
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inds mRNA with complementary sequence, resulting in
RNA cleavage or translational repression, depending on
he extent of sequence complementarity (reviewed by
han, 2010).
The ability to harness the RNAi pathway, either by the
ptake of synthetic siRNA into cells, or by the introduc-
ion of vectors that express short hairpin RNA (shRNA)
hat mimic  miRNA precursors, allows the silencing of vir-
ually any gene of any organism and has proved to be an
legant tool for the reverse genetic investigation of gene
unction. siRNA libraries are now available for humans
nd mice, which allow high throughput screening of
housands of genes simultaneously, which have expanded
ur knowledge and identiﬁed novel genes involved in cel-
ular pathways and host–pathogen interactions (Zhou et al.,
008; Jayaswal et al., 2010). Since nearly any gene can
e silenced the technology has great therapeutic poten-
ial, if the siRNAs can be delivered to the desired cells
r organs, and several siRNA therapeutics are currently
n phase II and III trials (reviewed by Whitehead et al.,
009). A major advantage of employing the RNAi path-
ay is that genes can be silenced in non-model species,
here reagents are limited but sequence information is
vailable. This is particularly true for farm animals, where
enome sequencing efforts have resulted in large sequence
esources, but there are limited reagents, e.g. antibodies,
vailable and few transgenic animals. Gene silencing by
iRNA are now routinely used in studies on cattle (Ma  and
orl, 2012), sheep (Smith et al., 2012), chickens (Qi et al.,
013), pigs (Shi et al., 2013) and salmon (Kumari et al.,
013) using cell lines and some primary cells. However,
here are difﬁculties introducing exogenous nucleotides,
ncluding siRNA, into certain primary cells, especially pri-
ary macrophages (reviewed by Zhang et al., 2009) and
tudies using siRNA to investigate macrophage genes lag
ehind those for other cell types. There are several rea-
ons for this difﬁculty, which relate to the function of
acrophages. Macrophages play several important roles
n the immune system. They detect pathogens and dan-
er signals and respond by phagocytosis and destruction
f pathogens, antigen presentation and the secretion of
mmunological mediators. For this they express many
nzymes that can degrade nucleotides and are primed
o react rapidly and vigorously to the presence of for-
ign particles. Our research focuses on investigating the
ole of bovine macrophages during infection with various
athogens, e.g. Theileria annulata (Jensen et al., 2009). As
art of an on-going project we wished to investigate the
unctional importance of macrophage expressed genes by
argeted silencing of genes in primary bovine monocyte-
erived macrophages (bMDM). To our knowledge the use
f siRNA or shRNA to knock-down gene expression in pri-
ary bovine macrophages has not been reported before.
herefore we set about investigating methods to silence
ovine macrophage genes utilizing the RNAi pathway. Viral
ectors, e.g. lentiviruses, can integrate into the genomes of
on-dividing cells, resulting in constitutive expression of
hRNA and long-term gene silencing (reviewed by Zhang
t al., 2009) and lentiviruses have successfully transduced
hRNA into primary human macrophages (Lee et al., 2003).
owever, one of the functions of macrophages is to respondmunopathology 158 (2014) 224–232 225
to the presence of viruses, which may  affect a subse-
quent response to challenge with the pathogen being
investigated. Therefore, our efforts have concentrated on
optimizing transient gene silencing in bMDM using the less
immunogenic siRNA.
There are two  predominant techniques that have
been successfully used to introduce siRNA into primary
macrophages derived from other, non-bovine species;
transient transfection (Zhang et al., 2005; Wati et al., 2007;
Behmoaras et al., 2008; Lietzen et al., 2011) and electropo-
ration (Wiese et al., 2010). Transient transfection involves
the use of cationic lipids which interact with negatively
charged RNA or DNA and form lipoplexes by electrostatic
forces (reviewed by Zuhorn et al., 2007) which are taken up
by endocytosis. Electroporation involves the application of
an external electric ﬁeld which temporarily increases cell
plasma permeability, causing pores to form in the plasma
membrane through which RNA or DNA can directly enter
cells (Neumann et al., 1982). Here we  report our investiga-
tion of siRNA gene silencing in bovine bMDM and describe
the optimization of siRNA delivery by transient transfection
and electroporation.
2. Materials and methods
2.1. Preparation of bovine monocyte-derived
macrophages (bMDM)
Peripheral blood from three female Holstein-Friesian
cattle, maintained at The Roslin Institute, was collected
aseptically into blood bags containing the anticoagulant
CPDA-1 (Sarstedt). All animals were clinically normal and
all experimental protocols were authorized under the
UK Animals (scientiﬁc procedures) Act, 1986. In addi-
tion, The Roslin Institute’s Animal Welfare and Ethics
Committee (AWEC) ensure compliance with all relevant
legislation and promote the adoption and developments
of the 3Rs (reduction, replacement, reﬁnement). Periph-
eral blood mononuclear cells (PBMC) were separated
by density gradient centrifugation as described previ-
ously (Jensen et al., 2006). The PBMC were resuspended
in RPMI-1640 medium without serum (Invitrogen) at
5 × 106 cells/ml and initially cultured for 2 h at 37 ◦C, after
which time the medium and non-adhered cells were
replaced with RPMI-1640 supplemented with 20% foetal
bovine serum (FBS), 4 mM l-glutamine and 50 M -
mercaptoethanol. The adhered cells were cultured for
7 days at 37 ◦C, with a change of medium on day 4.
During this time the monocytes within the PBMC were
observed to develop macrophage morphology and the
up-regulation of the macrophage markers; CD64, CD68, v-
maf  musculoaponeurotic ﬁbrosarcoma oncogene homolog
(avian) (MAF), macrophage scavenger receptor 1 (MSR1),
scavenger receptor class B, member 2 (SCARB2) and trigg-
ering receptor expressed on myeloid cells 2 (TREM2), was
detected by RT-PCR (see Supplementary File).
After 7 days the adhered cells were vigorously washed
three times with PBS to remove the remaining non-adhered
cells. The adherent cells were removed from the plates
by incubation with TrypLE Express (Invitrogen) and then
resuspended in RPMI-1640 supplemented with 20% FBS.
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The purity of the macrophage population was assessed
by ﬂow cytometry, using a mouse anti-bovine SIRPA
(CD172) antibody directly conjugated with RPE-Cy5 (AbD
Serotec: Cat. No. MCA2041C), which conﬁrmed that the
macrophage purity exceeded 90% (see Supplementary File).
All ﬂow cytometry analysis was carried out on a CyAn
ﬂow cytometer (Beckman Coulter) using the Summit soft-
ware.
2.2. siRNA duplexes
The AllStars negative control siRNA, which has no
homology to any known mammalian gene, labelled with
ﬂuorescein isothiocyanate (FITC) (Qiagen) was used to
assess the efﬁciency of siRNA uptake and as the neg-
ative control siRNA in the knock-down experiments.
As part of on-going studies, siRNA were designed for
the inﬂammasome-associated bovine Mediterranean fever
(MEFV), using the RefSeq sequence XM 002706315. The
siRNA were designed by Sigma–Aldrich and three siRNA
were purchased and tested. All three siRNA induced
target gene knock-down and the results for MEFV#3 (5′-
GTTGCTTAATAAATCCTTA-3′) are described here. Stocks
(20 M)  were prepared of each siRNA, which were aliquot-
ted and stored at −20 ◦C.
2.3. Transfection
The efﬁcacy of eleven transfection reagents to promote
uptake of the FITC-labelled siRNA was investigated. The
bMDM were seeded at 1 × 105 cells/well in 24 well plates.
After 3 h incubation at 37 ◦C, during which time the bMDM
had adhered to the plastic, the cells were transfected
with 50 nM siRNA. The transfection reagents; HiPerFect
(Qiagen), INTERFERin (Polyplus), Lipofectamine RNAiMAX
(Invitrogen), Lipofectamine 2000 (Invitrogen), Dharma-
FECT 1, DharmaFECT 2, DharmaFECT 3 and DharmaFECT
4 (Dharmacon), siPORT Amine (Ambion), X-tremeGENE
(Roche) and N-TER (Sigma–Aldrich) were used according
to the manufacturers’ instructions. After 16 h incubation
at 37 ◦C the bMDM were harvested and analyzed by ﬂow
cytometry.
To investigate the efﬁcacy of each siRNA to knock-
down expression of the target genes, the bMDM were
seeded at 2 × 105 cells/well in 24 well plates and, after
24 h incubation at 37 ◦C, were transfected with transfec-
tion reagent alone or with 50 nM siRNA. The transfection
reagents were used at the optimum conditions deter-
mined by the previous experiments. To investigate any
response of bMDM to the transfection reagents the bMDM
were either incubated at 37 ◦C for 48 h or the medium
was changed after 24 h and the bMDM cultured for a fur-
ther 24 h before being harvested and the RNA extracted.
To investigate MEFV knockdown, bMDM were incubated
at 37 ◦C for 24 h, then the medium was replaced and
bMDM were cultured for an additional 24 h. To stimulate
MEFV expression bMDM were activated with 100 ng/ml
Escherichia coli-derived lipopolysaccharide (LPS) (Sigma)
and bMDM were harvested and RNA extracted 2 h post
activation.munopathology 158 (2014) 224–232
2.4. Electroporation
The ability of electroporation to deliver FITC-labelled
AllStar negative control siRNA (Qiagen) into bMDM was ini-
tially investigated and the protocol optimized. Two  buffers
were tested; Opti-MEM I (Invitrogen) and siPORT siRNA
electroporation buffer (Ambion). The siRNA was trans-
ferred into 1 mm electrode gap cuvettes and either buffer
was  added to give a total volume of 50 l. The bMDM sus-
pension in either buffer, at 4 × 107 cells/ml, was added to
the cuvette and mixed by pipetting to give a ﬁnal vol-
ume  of 100 l, containing 2 × 105 cells and 1 M siRNA. The
cuvette was immediately pulsed at a range of voltage and
capacitance levels using a Gene Pulser electroporator (Bio-
Rad). The electroporated bMDM were incubated at 37 ◦C for
10 minutes before being transferred into 24 well plates and
the volume increased to 0.5 ml/well. After 16 h incubation
at 37 ◦C the bMDM were harvested and analyzed by ﬂow
cytometry.
The electroporation of target gene siRNA was carried
out using a scaled up version of the optimized conditions.
bMDM were resuspended at 1.2 × 107 cells/ml in Opti-
MEM  I and electroporated with 3 M siRNA at 300 V and
25 F. After 10 min  incubation at 37 ◦C the bMDM were
transferred into 6 well plates and the volume increased to
4 ml/well. Unless stated otherwise, the bMDM were incu-
bated at 37 ◦C for 48 h before being harvested and the RNA
was  extracted.
2.5. Quantiﬁcation of siRNA uptake and cytotoxicity
After 16 h incubation at 37 ◦C the bMDM transfected
or electroporated with FITC-labelled siRNA were har-
vested using TrypLE Express, washed with RPMI-1640
supplemented with 20% FBS and resuspended in 1 ml  PBS
supplemented with 0.5% FBS. Cell toxicity was  measured
by staining the cells with 1 M SYTOX Blue dead cell stain
(Invitrogen) according to the manufacturer’s protocol. The
bMDM were analyzed using a CyAn ﬂow cytometer (Beck-
man  Coulter), the bMDM population was  gated, by size
and complexity (see Supplementary File), and the percent-
age of FITC labelled and SYTOX Blue labelled bMDM was
measured.
2.6. Quantitative (q)RT-PCR analysis of target gene
knock-down and interferon response
Total RNA was extracted from the bMDM samples using
the RNeasy Mini Kit (Qiagen) according to the manu-
facturer’s instructions with on-column DNase digestion.
The quality and quantity of the resulting RNA was  deter-
mined by gel electrophoresis and NanoDrop ND-1000
spectrophotometer (Thermo Scientiﬁc). First strand cDNA
was  reverse transcribed from 0.1 to 0.5 g total RNA using
oligo(dT) primer and Superscript II (Invitrogen) according
to the manufacturer’s instructions. The resulting cDNA was
diluted 1:25 for all genes. The mRNA levels of MEFV and
selected type I interferon (IFN)-response genes were quan-
tiﬁed by qPCR using the FastStart Universal SYBR Green
mastermix (Roche) as described previously (Jensen et al.,
2009). Oligonucleotides were designed for the target gene
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EFV and the IFN-response gene interferon-induced pro-
ein with tetratricopeptide repeats 1 (IFIT1) using Primer3
Rozen and Skaletsky, 2000) and Netprimer (Biosoft
nternational) software. The sequences of the MEFV
ligonucleotides are 5′-GGACCCCTCAATCCAGAAAT-3′ and
′-GATGCTCCCCAATCATCATC-3′. The sequences of the
FIT1 oligonucleotides are 5′-GCTGCCAAGTTTTACCGAAG-
′ and 5′-CAAAGCCCTGTCTGGTGATG-3′. The relative quan-
ities of mRNA were calculated using the method described
y Pfafﬂ (2001), using the qRT-PCR results for chromo-
ome alignment maintaining phosphoprotein 1 (CHAMP1),
reviously known as Chromosome 13 open reading frame
, to calculate differences in the template RNA levels and
hereby standardize the results for the genes of interest
Jensen et al., 2009).
. Results and discussion
.1. Delivery of siRNA by transfection reagents
Liposome based transfection reagents provide a simple
nd cost-effective method to introduce siRNA into cells and
s therefore the method of choice for many researchers.
uccessful silencing of target genes in non-bovine primary
acrophages with siRNA delivered by transient transfec-
ion has been reported previously (Zhang et al., 2005; Wati
t al., 2007; Behmoaras et al., 2008; Lietzen et al., 2011).
.1.1. Screening of transfection reagents
We  initially tested the suitability of eleven commer-
ially available transfection reagents to promote siRNA
ptake by bMDM.  The preliminary experiments inves-
igated the efﬁcacy of three concentrations of each
ransfection reagent, within the range suggested by the
anufacturers, to promote the uptake of a FITC-labelled
on-target control (NTC) siRNA and the levels of cell
oxicity that were induced. The efﬁcacy of the eleven
ransfection reagents varied considerably, with the max-
mum percentage of bMDM taking up siRNA ranging
etween 19% and 86% cells with the different transfec-
ion reagents (Fig. 1). The reagents siPORT Amine, N-TER
nd DharmaFECT 1 failed to promote uptake of signiﬁcant
mounts of siRNA at the three different concentrations.
he use of DharmaFECT 2 and DharmaFECT 4 resulted
n siRNA up-take by a high proportion of bMDM,  but
aused considerable cell toxicity. The remaining transfec-
ion reagents: HiPerFect, INTERFERin, Lipofectamine 2000,
ipofectamine RNAiMAX, X-tremeGENE and DharmaFECT
 promoted good up-take of siRNA by bMDM,  without
ausing signiﬁcant cell death. The levels of siRNA up-take
ere observed to increase with increasing levels of the
ransfection reagents, except for X-tremeGENE and N-TER.
owever, this enhanced up-take was usually associated
ith increased cell toxicity.
.1.2. Investigation of potential off-target effects of
ransfection reagentsThe results described above illustrate that siRNA are
eadily taken up by bMDM using certain transfection
eagents. However, the suitability of transfection reagents
lso depends on the absence of the induction of off-targetmunopathology 158 (2014) 224–232 227
effects. The potential off-target effects induced by ﬁve
transfection reagents: INTERFERin, Lipofectamine 2000,
Lipofectamine RNAiMAX, X-tremeGENE and DharmaFECT
3, were investigated. These transfection reagents were
selected for further study on the basis of their combined
performance in terms of siRNA uptake and the cell toxicity
induced (Fig. 1). bMDM were cultured with each trans-
fection reagent, at the optimal concentration for siRNA
uptake, for 48 h without siRNA. This time-point was cho-
sen because several investigated siRNA induced maximal
gene-silencing at this time in previous optimization exper-
iments (data not shown). The expression of known type I
IFN-response genes was then measured at the mRNA level
by qRT-PCR. All ﬁve transfection reagents induced the up-
regulation of IFIT1, ranging from 25-fold for Lipofectamine
2000 to 395-fold up-regulation with X-tremeGENE (Fig. 2A
– 48 h incubation). Similar results were also measured
for other type I IFN-response genes; interferon induced
transmembrane protein 1 (IFITM1), myxovirus (inﬂuenza-
virus) resistance 1, interferon-inducible protein (MX1) and
2′,5′-oligoadenylate synthetase 1 (OAS1) (data not shown).
Off target transcriptional effects caused by the transfec-
tion reagents alone have been reported previously (Yoo
et al., 2006; Tagami et al., 2008; Lacaze et al., 2009). In
the absence of siRNA, Lipofectamine 2000 induced dif-
ferential expression of over 500 genes in murine bone
marrow derived macrophages, including many classic type
I IFN response genes (Lacaze et al., 2009). Interestingly, if
the medium was  changed 24 h post treatment with the
transfection reagents and the bMDM were cultured for a
further 24 h, the IFN-response was  not observed in bMDM
(Fig. 2A – 24 h incubation). The maximum fold increase
in IFIT1 mRNA that was measured was  6-fold induced
by Lipofectamine RNAiMAX. Therefore the transfection
reagents induce a response in bMDM,  but this appears
to be quickly dampened down by removing the stimulus.
However, using a similar protocol 92 genes were still differ-
entially expressed in human ﬁbrosarcoma cells (HT1080)
24 h after Lipofectamine 2000 was removed from the cul-
tures (Tagami et al., 2008).
3.1.3. Target gene knock-down using transfection
reagents
siRNA uptake does not guarantee target gene knock-
down (Lundberg et al., 2007; Metwally et al., 2012) and
therefore the ability of the ﬁve transfection reagents
to promote target gene knock-down using siRNA was
investigated. bMDM were treated with optimal concen-
trations of transfection reagent and siRNA against the
inﬂammasome-associated molecule MEFV, the function
of which we  are currently investigating. The bMDM were
cultured with transfection reagents and siRNA for 24 h
and then the medium was replaced and the bMDM were
cultured for a further 24 h. Levels of MEFV mRNA are below
detectable levels in resting bMDM and therefore bMDM
were stimulated with LPS to induce MEFV expression and
levels of MEFV mRNA were measured by qRT-PCR 2 h post
activation. The delivery of MEFV speciﬁc siRNA by the
transfection reagents INTERFERin, Lipofectamine 2000,
Lipofectamine RNAiMAX and DharmaFECT 3 reduced
the MEFV mRNA levels to between 13.0 and 34.0% of
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Fig. 1. Comparison of the efﬁcacy of eleven commercially available reagents to transfect siRNA into bovine monocyte-derived macrophages (bMDM).
bMDM were transfected with 50 nM FITC-labelled siRNA using three different concentrations of the transfection reagents HiPerFect (HPT), INTERFERin (INT),
Lipofectamine RNAiMAX (RNA), Lipofectamine 2000 (L2K), siPORT Amine (SPA), X-tremeGENE (XTG), N-TER (NTR) and DharmaFECT 1 (DF1), DharmaFECT 2
(DF2),  DharmaFECT 3 (DF3) and DharmaFECT 4 (DF4) following the manufacturer’s instructions. In addition bMDM were cultured with 50 nM FITC-labelled
 percen
 result isiRNA  in the absence of transfection reagents as a control (C). After 16 h the
of  viable bMDM (black diamonds) were measured by ﬂow cytometry. The
animals.
that measured in activated non-siRNA treated cells (NC)
(Fig. 2B). X-tremeGENE consistently failed to knock-down
mRNA for MEFV (Fig. 2B) or other target genes (data
not shown), illustrating that up-take of siRNA does not
equate with target gene knock-down. MEFV gene silencing
did not affect mRNA levels of the house-keeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
or those of other investigated genes (data not shown).
The transfection reagents alone and the NTC siRNA did
not diminish MEFV mRNA levels, but actually enhanced
them. The MEFV mRNA levels measured in Lipofectamine
RNAiMAX treated bMDM with (NTC) or without (TC) non-
target control siRNA are illustrated in Fig. 2B. On average
MEFV levels were 130% higher in TC than NC, although
this was not statistically signiﬁcant (P = 0.08). However,
MEFV mRNA levels in NTC samples were statistically
signiﬁcantly higher than in NC samples, on average 150%
greater (P < 0.05). Similar results were obtained for the
other transfection reagents. This is evidence that 24 h after
their removal transfection reagents are affecting bMDM
biology, by modifying the immune response induced by a
second stimuli. Furthermore, the scrambled siRNA, which
has no homology to any known mammalian gene, is having
an additional effect on MEFV mRNA expression.Speciﬁc anti-bovine MEFV antibodies are not com-
mercially available and constructing one was beyond
the scope of this work. Unfortunately attempts to detect
bovine MEFV using three different anti-human MEFVtage of bMDM transfected with FITC-siRNA (grey bars) and the percentage
s representative of three repeat experiments using bMDM from different
polyclonal antibodies, which due to MEFV sequence con-
servation are predicted to cross-react with bovine MEFV,
failed. Therefore we have been unable to directly conﬁrm
knock-down of MEFV at the protein level. However, we
have shown that knocking-down bovine MEFV, which
regulates inﬂammasome activity (Seshadri et al., 2007),
affects IL1B protein release (Jensen et al., in prep). This
result is in agreement with studies knocking down human
MEFV using a similar experimental design (Seshadri et al.,
2007), providing indirect evidence that the MEFV siRNA is
reducing bovine MEFV at the protein level.
Amongst the eleven transfection reagents investigated,
Lipofectamine 2000, Lipofectamine RNAiMAX and Dhar-
maFECT 3 consistently gave the best results, in terms
of siRNA uptake and target gene knockdown with min-
imal cell toxicity and type I IFN response induction.
Therefore, all three transfection reagents appear suit-
able for use in bMDM.  Lipofectamine 2000 and RNAiMAX
have successfully been used for siRNA gene silencing
in murine bone-marrow derived macrophages (Lacaze
et al., 2009) and human monocyte-derived macrophages
(hMDM) (Wati et al., 2007) respectively. However, in
another study siRNA were delivered into hMDM using
DharmaFECT 1 (Behmoaras et al., 2008) which was unsuit-
able for use in bMDM,  resulting in low levels of siRNA
uptake. Furthermore, siPORT Amine was  found to be the
best transfection reagent for siRNA delivery into porcine
alveolar macrophages (Zhang et al., 2005), which failed to
K. Jensen et al. / Veterinary Immunology and Immunopathology 158 (2014) 224–232 229
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Fig. 2. Transient transfection reagents induce a type I interferon (IFN)-response in bovine monocyte-derived macrophages (bMDM) in the absence of
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measured by qRT-PCR. The results are expressed as the IFIT1 mRNA fold difference compared to that measured in untreated cells (NC). Error bars denote the
variation between three technical replicates. (B) bMDM were transfected with MEFV siRNA using the ﬁve transfection reagents for 24 h before the medium
was  replaced. MEFV mRNA levels in bMDM transfected with (NTC) and without (TC) non-target control siRNA using Lipofectamine RNAiMAX were also
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acilitate siRNA uptake by bMDM.  Therefore, there is con-
iderable variation in the efﬁcacy of transfection reagents
o deliver siRNA into macrophages derived in different
ays and from different species.
.2. Delivery of siRNA by electroporation
The majority of cationic liposome-delivered siRNAs
nter cells by endocytosis (Lu et al., 2009). The resulting
ff-target immune response of cells to siRNA and trans-
ection reagents has been associated with their presence
n the endosome (Sioud, 2005; Yoo et al., 2006). An alter-
ative approach to introduce siRNA into cells is the use
f electroporation, the application of an external electrical
eld which temporarily increases cell plasma permeabil-
ty (Neumann et al., 1982), thus delivering siRNA directly
nto the cell cytoplasm. Using this technique can prevent
he sequence-speciﬁc immune response induced by siRNA
Sioud, 2005) and has successfully been used to intro-
uce siRNA into primary murine bone-marrow derived
acrophages, resulting in target gene knock-down (Wiese
t al., 2010). Therefore, the suitability of this approach to
eliver siRNA for targeted gene knock-down in bMDM was
nvestigated..2.1. Optimization of siRNA uptake by electroporation
Initially cell viability and uptake of FITC-labelled NTC
iRNA were optimized. The cells were tested in two media, results are expressed as the percentage MEFV mRNA detected compared
plicates. The results are representative of three repeat experiments using
Opti-MEM I and siPORT siRNA electroporation buffer, and
the voltage and capacitance settings were adjusted. The
different conditions altered the uptake of siRNA and cell
viability considerably (Fig. 3). The siPORT siRNA electro-
poration buffer was  not suitable for use with bMDM, its
use resulted in over 80% cell death in all electropora-
tion conditions tested. In contrast, the use of Opti-MEM
I reduced the level of cell toxicity, although this varied
considerably depending on the electroporation conditions.
The highest level of siRNA uptake, exceeding 60%, was
observed at voltage 200 V and 250 V with capacitance set
at 125 F, although these maximal values were lower
than observed with the transfection reagents (Fig. 1).
However, these conditions induced relatively high lev-
els of cell toxicity, killing over 30% bMDM.  Taking into
account the siRNA uptake and cell toxicity induced, the
electroporation conditions 300 V and 25 F were optimal
(Fig. 3) and these settings were used in the later experi-
ments.
3.2.2. Investigation of target gene knock-down and
potential off-target effects with electroporation
The ability of electroporated siRNA to induce target gene
knock-down in bMDM was  investigated. bMDM were elec-
troporated with MEFV siRNA, NTC siRNA or in the absence
of siRNA and MEFV mRNA levels were measured 2 h post
activation of bMDM incubated with siRNA for 48 h. MEFV
mRNA levels were reduced by 75% in bMDM electroporated
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Fig. 3. Optimization of siRNA uptake by electroporation. The ability of bovine monocyte-derived macrophages (bMDM) in different buffers, Opti-MEM and
siPORT siRNA electroporation buffer, to take up 1 M FITC-labelled siRNA after electroporation at various voltage and capacitance settings was compared.
After  16 h the percentage of bMDM transfected with FITC-siRNA (grey bars) and the percentage of viable bMDM (black diamonds) were measured by ﬂow
cytometry. The result is representative of three repeat experiments using bMDM from different animals.
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Fig. 4. Electroporation is an effective method for siRNA uptake in bovine monocyte-derived macrophages (bMDM) without inducing a type I interferon
(IFN)  response. bMDM were electroporated without siRNA (EC), with MEFV siRNA or non-target control siRNA (NTC siRNA). (A) After 48 h the electroporated
bMDM were activated with 100 ng/ml LPS for 2 h. The results are expressed as the percentage MEFV mRNA detected compared to that measured in untreated
cells  (NC). Error bars denote the variation between three technical replicates. (B) After 48 h cells were harvested and mRNA levels of the IFN-response gene
interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) were measured by qRT-PCR. The results are expressed as the IFIT1 mRNA fold difference
compared to that measured in NC. Error bars denote the variation between three technical replicates. The results are representative of three repeat
experiments using bMDM from different animals.
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ith MEFV siRNA (Fig. 4A). This is comparable to levels
easured in bMDM transfected with this siRNA (Fig. 2B).
either the electroporation process nor the presence of
he siRNA was associated with any change in IFIT1 levels
Fig. 4B) or any other IFN-response gene investigated (data
ot shown). Therefore electroporation is a suitable alter-
ative to the use of transfection reagents to deliver siRNA
nto bMDM.
.3. Conclusions
The results reported here demonstrate that, contrary to
he dogma that primary macrophages are difﬁcult to trans-
ect, primary bMDM can be electroporated or transfected
ith siRNA resulting in good levels of target gene silencing.
he methodologies described above have now been used
o successfully silence nine genes in bMDM (manuscripts
n preparation). It is hoped that these methodologies will
rovide a starting point for optimizing siRNA use in pri-
ary macrophages from other species and other primary
ells which are regarded as being hard to transfect, e.g.
endritic cells. Several of the tested transfection reagents
ppear suitable for use: DharmaFECT 3, Lipofectamine
000 and RNAiMAX. Electroporated siRNA silenced the
EFV gene to a comparable level as transfected siRNA,
ut the procedure resulted in more cell death and the
emaining cells were less robust than transfected cells
n down-stream activation studies (data not shown). The
ransfection protocols allow siRNA uptake by adhered
ells and therefore it is much easier to reapply siRNA
o bMDM,  thereby extending the period of gene silenc-
ng, than by electroporation. The choice of transfecting or
lectroporating siRNA into cells depends on the individ-
al experiments. The fragility of electroporated cells to
hallenge means that the use of transfection reagents is
ore suitable than electroporation for our work investi-
ating the role of host macrophage genes in the response
o infection. However, the increased expression of MEFV
ith transfection reagent treatment illustrates that both
ethodologies do affect macrophages and highlights the
mportance of the inclusion of suitable controls in siRNA
xperiments.
onﬂict of interest statement
The authors declare that no conﬂicting ﬁnancial inter-
sts exist.
cknowledgements
We  wish to thank Dharmacon, Polyplus, Roche and
igma–Aldrich for providing their transfection reagents
ree of charge. We would also like to thank Invitro-
en, Ambion and Qiagen for supplying their transfection
eagents at a discount. This work was supported by
he European Framework 7 small collaborative project
ACROSYS (FP7-KBBE-2007-1-1-2). EJG was also sup-
orted by the Biotechnology and Biological Sciences
esearch Council (Institute Strategic Programme Grant).munopathology 158 (2014) 224–232 231
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/
j.vetimm.2014.02.002.
References
Behmoaras, J., Bhangal, G., Smith, J., McDonald, K., Mutch, B., Lai, P.C.,
Domin, J., Game, L., Salama, A., Foxwell, B.M., Pusey, C.D., Cook, H.T.,
Aitman, T.J., 2008. Jund is a determinant of macrophage activation
and is associated with glomerulonephritis susceptibility. Nat. Genet.
40,  553–559.
Dykxhoorn, D.M., Lieberman, J., 2005. The silent revolution: RNA interfer-
ence as basic biology, research tool, and therapeutic. Annu. Rev. Med.
56, 401–423.
Elbashir, S.M., Harborth, J., Lendeckel, W.,  Yalcin, A., Weber, K., Tuschl, T.,
2001. Duplexes of 21-nucleotide RNAs mediate RNA interference in
cultured mammalian cells. Nature 411, 494–498.
Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., Mello, C.C., 1998.
Potent and speciﬁc genetic interference by double-stranded RNA in
Caenorhabditis elegans. Nature 391, 806–811.
Jayaswal, S., Kamal, M.A., Dua, R., Gupta, S., Majumdar, T., Das, G., Kumar,
D.,  Rao, K.V.S., 2010. Identiﬁcation of host-dependent survival factors
for  intracellular Mycobacterium tuberculosis through an siRNA screen.
PLoS Pathog. 6, e10000839.
Jensen, K., Talbot, R., Paxton, E., Waddington, D., Glass, E.J., 2006.
Development and validation of a bovine macrophage speciﬁc cDNA
microarray. BMC  Genom. 7, 224.
Jensen, K., Makins, G.D., Kaliszewska, A., Hulme, M.J., Paxton, E., Glass,
E.J.,  2009. The protozoan parasite Theileria annulata alters the dif-
ferentiation state of the infected macrophages and suppresses MAF
transcription factors. Int. J. Parasitol. 39, 1099–1108.
Kumari, J., Bøgwald, J., Dalmo, R.A., 2013. Eomesodermin of atlantic
salmon: an important regulator of cytolytic gene and inter-
feron gamma expression in spleen lymphocytes. PLoS ONE 8,
e55893.
Lacaze, P., Raza, S., Sing, G., Page, D., Forster, T., Storm, P., Craigon, M.,
Awad, T., Ghazal, P., Freeman, T.C., 2009. Combined genome-wide
expression proﬁling and targeted RNA interference in primary mouse
macrophages reveals perturbation of transcriptional networks asso-
ciated with interferon signalling. BMC  Genom. 10, 372.
Lee, M.T.M., Coburn, G.A., McClure, M.O., Cullen, B.R., 2003. Inhibition
of  human immunodeﬁciency virus type 1 replication in primary
macrophages by using Tat- or CCR5-speciﬁc small interfering RNA s
expressed from a lentivirus vector. J. Virol. 77, 11964–11972.
Lietzen, N., Ohman, T., Rintahaka, J., Julkunen, I., Aittokallio, T., Matikainen,
S.,  Nyman, T.A., 2011. Quantitiative subcellular proteome and
secretome proﬁling of inﬂuenza A virus-infected human primary
macrophages. PLoS Pathog. 7, e1001340.
Lu, J.J., Langer, R., Chen, J., 2009. A novel mechanism is involved in
cationic lipid-mediated functional siRNA delivery. Mol. Pharmaceut.
6,  763–771.
Lundberg, P., El-Andaloussi, S., Sütlü, T., Johansson, H., Langel, Ü.,
2007. Delivery of short interfering RNA using endosomolytic cell-
penetrating peptides. FASEB J. 21, 2664–2671.
Ma, L., Corl, B.A., 2012. Transcriptional regulation of lipid synthesis in
bovine mammary epithelial cells by sterol regulatory element binding
protein-1. J. Dairy Sci. 95, 3743–3755.
Metwally, A.A., Reelfs, O., Pourzand, C., Blagbrough, I.S., 2012. Efﬁcient
silencing of EGFP reporter gene with siRNA delivered by asymmetrical
N4,N9-diacyl spermines. Mol. Pharm. 9, 1862–1876.
Neumann, E., Schaefer-Ridder, M.,  Wang, Y., Hofschneider, P.H., 1982.
Gene transfer into mouse lyoma cells by electroporation in high elec-
tric ﬁelds. EMBO J. 1, 841–845.
Pfafﬂ, M.W.,  2001. A new mathematical model for relative quantiﬁcation
in  real-time RT-PCR. Nucleic Acids Res. 29, e45.
Qi, R., Feng, M., Tan, X., Gan, L., Yan, G., Sun, C., 2013. FATP1 silence
inhibits the differentiation and induces the apoptosis in chicken
preadipocytes. Mol. Biol. Rep. 40, 2907–2914.
Rozen, S., Skaletsky, H.J., 2000. Primer3 on the WWW  for general users
and for biologist programmers. In: Krawetz, S., Misener, S. (Eds.),
Bioinformatics Methods and Protocols: Methods in Molecular Biology.
Humana Press, Totowa, pp. 365–386.
Seshadri, S., Duncan, M.D., Hart, J.M., Gavrilin, M.A., Wewers, M.D.,
2007. Pyrin levels in human monocytes and monocyte-derived
y and Im232 K. Jensen et al. / Veterinary Immunolog
macrophages regulate IL-1 processing and release. J. Immunol. 179,
1274–1281.
Shan, G., 2010. RNA interference as a gene knockdown technique. Int. J.
Biochem. Cell Biol. 42, 1243–1251.
Shi, Z., Sun, J., Guo, H., Yang, Z., Ma,  Z., Tu, C., 2013. Down-
regulation of cellular protein heme oxygenase 1 inhibits proliferation
of classical swine fever virus in PK-15 cells. Virus Res. 173,
315–320.
Sioud, M.,  2005. Induction of inﬂammatory cytokines and inter-
feron responses by double-stranded and single-stranded siRNAs is
sequence-dependent and requires endosomal localization. J. Mol. Biol.
348, 1079–1090.
Smith, L.B., Belanger, J.M., Oberbauer, A.M., 2012. Fibroblast growth factor
receptor 3 effects on proliferation and telomerase activity in sheep
growth plate chondrocytes. J. Anim. Sci. Biotechnol. 3, 39.
Tagami, T., Hirose, K., Barichello, J.M., Ishida, T., Kiwada, H., 2008. Global
gene expression proﬁling in cultured cells is strongly inﬂuenced by
treatment with siRNA-cationic liposome complexes. Pharm. Res. 25,
2497–2504.
Wati, S., Li, P., Burrell, C.J., Carr, J.M., 2007. Dengue virus (DV) replication
in monocyte-derived macrophages is not affected by tumour necrosis
factor alpha (TNF-), and DV infection induces altered responsiveness
to  TNF- stimulation. J. Virol. 81, 10161–10171.munopathology 158 (2014) 224–232
Wiese, M.,  Castiglione, K., Hensel, M.,  Schleicher, U., Bogdan, C.,
Jantsch, J., 2010. Small interfering RNA (siRNA) delivery into murine
bone-marrow derived macrophages by electroporation. J. Immunol.
Methods 353, 102–110.
Whitehead, K.A., Langer, R., Anderson, D.G., 2009. Knocking down barriers:
advances in siRNA delivery. Nat. Rev. 8, 129–138.
Yoo, J.W., Hong, S.W., Kim, S., Lee, D., 2006. Inﬂammatory cytokine induc-
tion by siRNAs is cell type- and transfection reagent-speciﬁc. Biochem.
Biophys. Res. Commun. 347, 1053–1058.
Zhang, X., Stieber, N., Rutherford, M.S., 2005. An interfering RNA proto-
col  for primary porcine alveolar macrophages. Anim. Biotechnol. 16,
31–40.
Zhang, X., Edwards, J.P., Mosser, D.M., 2009. The expression of exogenous
genes in macrophages: obstacles and opportunities. In: Reiner, N.E.
(Ed.), Macrophages and Dendritic Cells, Methods in Molecular Biology.
Humana Press, Totowa, pp. 123–143.
Zhou, H., Xu, M.,  Huang, Q., Gates, A.T., Zhang, X.D., Castle, J.C., Stec, E.,
Ferrar, M.,  Strulovici, B., Hazuda, D.J., Espeseth, A.S., 2008. Genome-
scale RNAi screen for host factors required for HIV replication. Cell
Host Microbe 4, 495–504.
Zuhorn, I.S., Engberts, J.B.F.N., Hoekstra, D., 2007. Gene delivery by
cationic lipid vectors: overcoming cellular barriers. Eur. Biophys. J.
36, 349–362.
